SAN.PA · Sanofi S.A.

EURO STOXX 50 · Euronext Paris

Risiko 5/10 · Pharma Major · €79.38 ▲ 2.04%

Kennzahlen

• Price €79.38
• Market cap €95.0B
• P/E (ttm) 20.05
• Div yield 5.30%
• 52-wk range €71.25 – €91.15

Wichtigste Risiken

• Dupixent patent cliff / biosimilar risk (Revenue concentration, ~40% of sales) — HIGH
• GLP-1 competitive displacement (Obesity pipeline behind Novo and Lilly) — HIGH
• R&D pipeline execution (Late-stage failures in oncology and immunology) — MED
• Vaccine franchise pricing pressure (Flu and Beyfortus reimbursement negotiations) — MED

Fazit

Dupixent's blockbuster status buys time, but Sanofi must demonstrate a credible post-patent pipeline before the 2031 biosimilar window to sustain current valuations.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.